Aromasin

Name: Aromasin

Other uses for this medicine

Exemestane is also sometimes used to treat a certain type of breast cancer in women who not yet experienced menopause. Talk to your doctor about the risks of using this medication for your condition.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What should I do if I forget a dose?

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

In case of emergency/overdose

In case of overdose, call your local poison control center at 1-800-222-1222. If the victim has collapsed or is not breathing, call local emergency services at 911.

Exemestane Interactions

This medicine can pass into body fluids (urine, feces, vomit). Caregivers should wear rubber gloves while cleaning up a patient's body fluids, handling contaminated trash or laundry or changing diapers. Wash hands before and after removing gloves. Wash soiled clothing and linens separately from other laundry.

This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.

Other drugs may interact with exemestane, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using.

How supplied

Dosage Forms And Strengths

AROMASIN Tablets are round, biconvex, and off-white to slightly gray. Each tablet contains 25 mg of exemestane. The tablets are printed on one side with the number “7663” in black.

Storage And Handling

AROMASIN Tablets are round, biconvex, and off-white to slightly gray. Each tablet contains 25 mg of exemestane. The tablets are printed on one side with the number “7663” in black.

AROMASIN is packaged in HDPE bottles with a child-resistant screw cap, supplied in packs of 30 tablets.

30-tablet HDPE bottle      NDC 0009-7663-04

Store at 25°C (77ºF); excursions permitted to 15°–30°C (59°–86°F) [see USP Controlled Room Temperature].

Distributed by: Pharmacia & Upjohn Company, Division of Pfizer Inc, NY, NY 10017. Revised: July 2016

Clinical pharmacology

Mechanism Of Action

Breast cancer cell growth may be estrogen-dependent. Aromatase is the principal enzyme that converts androgens to estrogens both in pre-and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues.

Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme, causing its inactivation, an effect also known as “suicide inhibition.” Exemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has no detectable effect on adrenal biosynthesis of corticosteroids or aldosterone. Exemestane has no effect on other enzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibiting the aromatase enzyme.

Pharmacodynamics

Effect On Estrogens

Multiple doses of exemestane ranging from 0.5 to 600 mg/day were administered to postmenopausal women with advanced breast cancer. Plasma estrogen (estradiol, estrone, and estrone sulfate) suppression was seen starting at a 5-mg daily dose of exemestane, with a maximum suppression of at least 85% to 95% achieved at a 25-mg dose. Exemestane 25 mg daily reduced whole body aromatization (as measured by injecting radiolabeled androstenedione) by 98% in postmenopausal women with breast cancer. After a single dose of exemestane 25 mg, the maximal suppression of circulating estrogens occurred 2 to 3 days after dosing and persisted for 4 to 5 days.

Effect On Corticosteroids

In multiple-dose trials of doses up to 200 mg daily, exemestane selectivity was assessed by examining its effect on adrenal steroids. Exemestane did not affect cortisol or aldosterone secretion at baseline or in response to ACTH at any dose. Thus, no glucocorticoid or mineralocorticoid replacement therapy is necessary with exemestane treatment.

Other Endocrine Effects

Exemestane does not bind significantly to steroidal receptors, except for a slight affinity for the androgen receptor (0.28% relative to dihydrotestosterone). The binding affinity of its 17dihydrometabolite for the androgen receptor, however, is 100 times that of the parent compound. Daily doses of exemestane up to 25 mg had no significant effect on circulating levels of androstenedione, dehydroepiandrosterone sulfate, or 17-hydroxyprogesterone, and were associated with small decreases in circulating levels of testosterone. Increases in testosterone and androstenedione levels have been observed at daily doses of 200 mg or more. A dose-dependent decrease in sex hormone binding globulin (SHBG) has been observed with daily exemestane doses of 2.5 mg or higher. Slight, nondose-dependent increases in serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels have been observed even at low doses as a consequence of feedback at the pituitary level. Exemestane 25 mg daily had no significant effect on thyroid function [free triiodothyronine (FT3), free thyroxine (FT4), and thyroid stimulating hormone (TSH)].

Coagulation And Lipid Effects

In study 027 of postmenopausal women with early breast cancer treated with exemestane (N=73) or placebo (N=73), there was no change in the coagulation parameters activated partial thromboplastin time [APTT], prothrombin time [PT], and fibrinogen. Plasma HDL cholesterol was decreased 6–9% in exemestane treated patients; total cholesterol, LDL cholesterol, triglycerides, apolipoprotein-A1, apolipoprotein-B, and lipoprotein-a were unchanged. An 18% increase in homocysteine levels was also observed in exemestane treated patients compared with a 12% increase seen with placebo.

Pharmacokinetics

Following oral administration to healthy postmenopausal women, plasma concentrations of exemestane decline polyexponentially with a mean terminal half-life of about 24 hours. The pharmacokinetics of exemestane are dose proportional after single (10 to 200 mg) or repeated oral doses (0.5 to 50 mg). Following repeated daily doses of exemestane 25 mg, plasma concentrations of unchanged drug are similar to levels measured after a single dose. Pharmacokinetic parameters in postmenopausal women with advanced breast cancer following single or repeated doses have been compared with those in healthy, postmenopausal women. After repeated dosing, the average oral clearance in women with advanced breast cancer was 45% lower than the oral clearance in healthy postmenopausal women, with corresponding higher systemic exposure. Mean AUC values following repeated doses in women with breast cancer (75.4 ng•h/mL) were about twice those in healthy women (41.4 ng•h/mL).

Absorption

Following oral administration, exemestane appeared to be absorbed more rapidly in women with breast cancer than in the healthy women, with a mean -tmax of 1.2 hours in the women with breast cancer and 2.9 hours in healthy women. Approximately 42% of radiolabeled exemestane was absorbed from the gastrointestinal tract. A high-fat breakfast increased AUC and Cmax of exemestane by 59% and 39%, respectively, compared to fasted state.

Distribution

Exemestane is distributed extensively into tissues. Exemestane is 90% bound to plasma proteins and the fraction bound is independent of the total concentration. Albumin and α11-acid glycoprotein both contribute to the binding. The distribution of exemestane and its metabolites into blood cells is negligible.

Metabolism

Exemestane is extensively metabolized, with levels of the unchanged drug in plasma accounting for less than 10% of the total radioactivity. The initial steps in the metabolism of exemestane are oxidation of the methylene group in position 6 and reduction of the 17-keto group with subsequent formation of many secondary metabolites. Each metabolite accounts only for a limited amount of drug-related material. The metabolites are inactive or inhibit aromatase with decreased potency compared with the parent drug. One metabolite may have androgenic activity [see Pharmacodynamics]. Studies using human liver preparations indicate that cytochrome P 450 3A4 (CYP 3A4) is the principal isoenzyme involved in the oxidation of exemestane. Exemestane is metabolized also by aldoketoreductases.

Elimination

Following administration of radiolabeled exemestane to healthy postmenopausal women, the cumulative amounts of radioactivity excreted in urine and feces were similar (42 ± 3% in urine and 42 ± 6% in feces over a 1-week collection period). The amount of drug excreted unchanged in urine was less than 1% of the dose.

Specific Populations

Geriatric

Healthy postmenopausal women aged 43 to 68 years were studied in the pharmacokinetic trials. Age-related alterations in exemestane pharmacokinetics were not seen over this age range.

Gender

The pharmacokinetics of exemestane following administration of a single, 25-mg tablet to fasted healthy males (mean age 32 years) were similar to the pharmacokinetics of exemestane in fasted healthy postmenopausal women (mean age 55 years).

Race

The influence of race on exemestane pharmacokinetics has not been evaluated.

Hepatic Impairment

The pharmacokinetics of exemestane have been investigated in subjects with moderate or severe hepatic impairment (Childs-Pugh B or C). Following a single 25-mg oral dose, the AUC of exemestane was approximately 3 times higher than that observed in healthy volunteers.

Renal Impairment

The AUC of exemestane after a single 25-mg dose was approximately 3 times higher in subjects with moderate or severe renal insufficiency (creatinine clearance <35 mL/min/1.73 m2) compared with the AUC in healthy volunteers.

Pediatric

The pharmacokinetics of exemestane have not been studied in pediatric patients.

Drug Interactions

Exemestane does not inhibit any of the major CYP isoenzymes, including CYP 1A2, 2C9, 2D6, 2E1, and 3A4.

In a pharmacokinetic interaction study of 10 healthy postmenopausal volunteers pretreated with potent CYP 3A4 inducer rifampicin 600 mg daily for 14 days followed by a single dose of exemestane 25 mg, the mean plasma Cmax and AUC 0–∞ of exemestane were decreased by 41% and 54%, respectively [see DOSAGE AND ADMINISTRATION and DRUG INTERACTIONS].

In a clinical pharmacokinetic study, coadministration of ketoconazole, a potent inhibitor of CYP 3A4, has no significant effect on exemestane pharmacokinetics. Although no other formal drug-drug interaction studies with inhibitors have been conducted, significant effects on exemestane clearance by CYP isoenzyme inhibitors appear unlikely.

Clinical Studies

Adjuvant Treatment In Early Breast Cancer

The Intergroup Exemestane Study 031 (IES) was a randomized, double-blind, multicenter, multinational study comparing exemestane (25 mg/day) vs. tamoxifen (20 or 30 mg/day) in postmenopausal women with early breast cancer. Patients who remained disease-free after receiving adjuvant tamoxifen therapy for 2 to 3 years were randomized to receive an additional 3 or 2 years of AROMASIN or tamoxifen to complete a total of 5 years of hormonal therapy.

The primary objective of the study was to determine whether, in terms of disease-free survival, it was more effective to switch to AROMASIN rather than continuing tamoxifen therapy for the remainder of five years. Disease-free survival was defined as the time from randomization to time of local or distant recurrence of breast cancer, contralateral invasive breast cancer, or death from any cause.

The secondary objectives were to compare the two regimens in terms of overall survival and long-term tolerability. Time to contralateral invasive breast cancer and distant recurrence-free survival were also evaluated.

A total of 4724 patients in the intent-to-treat (ITT) analysis were randomized to AROMASIN (exemestane tablets) 25 mg once daily (N = 2352) or to continue to receive tamoxifen once daily at the same dose received before randomization (N = 2372). Demographics and baseline tumor characteristics are presented in Table 5. Prior breast cancer therapy is summarized in Table 6.

Table 5. Demographic and Baseline Tumor Characteristics from the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)

Parameter Exemestane
(N = 2352)
Tamoxifen
(N = 2372)
Age (years):
Median age (range) 63.0 (38.0 – 96.0) 63.0 (31.0 – 90.0)
Race, n (%):
Caucasian 2315 (98.4) 2333 (98.4)
Hispanic 13 (0.6) 13 (0.5)
Asian 10 (0.4) 9 (0.4)
Black 7 (0.3) 10 (0.4)
Other/not reported 7 (0.3) 7 (0.3)
Nodal status, n (%):
Negative 1217 (51.7) 1228 (51.8)
Positive 1051 (44.7) 1044 (44.0)
  1–3 Positive nodes 721 (30.7) 708 (29.8)
  4–9 Positive nodes 239 (10.2) 244 (10.3)
  >9 Positive nodes 88 (3.7) 86 (3.6)
  Not reported 3 (0.1) 6 (0.3)
Unknown or missing 84 (3.6) 100 (4.2)
Histologic type, n (%):
Infiltrating ductal 1777 (75.6) 1830 (77.2)
Infiltrating lobular 341 (14.5) 321 (13.5)
Other 231 (9.8) 213 (9.0)
Unknown or missing 3 (0.1) 8 (0.3)
Receptor status*, n (%):
ER and PgR Positive 1331 (56.6) 1319 (55.6)
ER Positive and PgR Negative/Unknown 677 (28.8) 692 (29.2)
ER Unknown and PgR Positive**/Unknown 288 (12.2) 291 (12.3)
ER Negative and PgR Positive 6 (0.3) 7 (0.3)
ER Negative and PgR Negative/Unknown (none positive) 48 (2.0) 58 (2.4)
Missing 2 (0.1) 5 (0.2)
Tumor Size, n (%):
≤ 0.5 cm 58 (2.5) 46 (1.9)
> 0.5 – 1.0 cm 315 (13.4) 302 (12.7)
> 1.0 – 2 cm 1031 (43.8) 1033 (43.5)
> 2.0 – 5.0 cm 833 (35.4) 883 (37.2)
> 5.0 cm 62 (2.6) 59 (2.5)
Not reported 53 (2.3) 49 (2.1)
Tumor Grade, n (%):
G1 397 (16.9) 393 (16.6)
G2 977 (41.5) 1007 (42.5)
G3 454 (19.3) 428 (18.0)
G4 23 (1.0) 19 (0.8)
Unknown/Not Assessed/Not reported 501 (21.3) 525 (22.1)
* Results for receptor status include the results of the post-randomization testing of specimens from subjects for whom receptor status was unknown at randomization.
** Only one subject in the exemestane group had unknown ER status and positive PgR status.

Table 6. Prior Breast Cancer Therapy of Patients in the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)

Parameter Exemestane
(N = 2352)
Tamoxifen
(N = 2372)
Type of surgery, n (%):
Mastectomy 1232 (52.4) 1242 (52.4)
Breast-conserving 1116 (47.4) 1123 (47.3)
Unknown or missing 4 (0.2) 7 (0.3)
Radiotherapy to the breast, n (%):    
Yes 1524 (64.8) 1523 (64.2)
No 824 (35.5) 843 (35.5)
Not reported 4 (0.2) 6 (0.3)
Prior therapy, n (%):
Chemotherapy 774 (32.9) 769 (32.4)
Hormone replacement therapy 567 (24.1) 561 (23.7)
Bisphosphonates 43 (1.8) 34 (1.4)
Duration of tamoxifen therapy at randomization (months):
Median (range) 28.5 (15.8 – 52.2) 28.4 (15.6 – 63.0)
Tamoxifen dose, n (%):
20 mg 2270 (96.5) 2287 (96.4)
30 mg* 78 (3.3) 75 (3.2)
Not reported 4 (0.2) 10 (0.4)
*The 30 mg dose was used only in Denmark, where this dose was the standard of care.

After a median duration of therapy of 27 months and with a median follow-up of 34.5 months, 520 events were reported, 213 in the AROMASIN group and 307 in the tamoxifen group (Table 7).

Table 7. Primary Endpoint Events (ITT Population)

Event First Events N (%)
  Exemestane
(N = 2352)
Tamoxifen
(N = 2372)
Loco-regional recurrence 34 (1.45) 45 (1.90)
Distant recurrence 126 (5.36) 183 (7.72)
Second primary – contralateral breast cancer 7 (0.30) 25 (1.05)
Death – breast cancer 1 (0.04) 6 (0.25)
Death – other reason 41 (1.74) 43 (1.81)
Death – missing/unknown 3 (0.13) 5 (0.21)
Ipsilateral breast cancer 1 (0.04) 0
Total number of events 213 (9.06) 307 (12.94)

Disease-free survival in the intent-to-treat population was statistically significantly improved [Hazard Ratio (HR) = 0.69, 95% CI: 0.58, 0.82, P = 0.00003, Table 8, Figure 1] in the AROMASIN arm compared to the tamoxifen arm. In the hormone receptor-positive subpopulation representing about 85% of the trial patients, disease-free survival was also statistically significantly improved (HR = 0.65, 95% CI: 0.53, 0.79, P = 0.00001) in the AROMASIN arm compared to the tamoxifen arm. Consistent results were observed in the subgroups of patients with node negative or positive disease, and patients who had or had not received prior chemotherapy.

An overall survival update at 119 months median follow-up showed no significant difference between the two groups, with 467 deaths (19.9%) occurring in the AROMASIN group and 510 deaths (21.5%) in the tamoxifen group.

Table 8. Efficacy Results from the IES Study in Postmenopausal Women with Early Breast Cancer

ITT Population Hazard Ratio (95% CI) p-value
(log-rank test)
Disease-free survival 0.69 (0.58–0.82) 0.00003
Time to contralateral breast cancer 0.32 (0.15–0.72) 0.00340
Distant recurrence-free survival 0.74 (0.62–0.90) 0.00207
Overall survival 0.86 (0.67–1.10) 0.22962
ER and/or PgR positive    
Disease-free survival 0.65 (0.53–0.79) 0.00001
Time to contralateral breast cancer 0.22 (0.08–0.57) 0.00069
Distant recurrence-free survival 0.73 (0.59–0.90) 0.00367
Overall survival 0.91 (0.81–1.04) 0.16*
*Not adjusted for multiple testing.

Figure 1. Disease-Free Survival in the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)

Treatment Of Advanced Breast Cancer

Exemestane 25 mg administered once daily was evaluated in a randomized double-blind, multicenter, multinational comparative study and in two multicenter single-arm studies of postmenopausal women with advanced breast cancer who had disease progression after treatment with tamoxifen for metastatic disease or as adjuvant therapy. Some patients also have received prior cytotoxic therapy, either as adjuvant treatment or for metastatic disease.

The primary purpose of the three studies was evaluation of objective response rate (complete response [CR] and partial response [PR]). Time to tumor progression and overall survival were also assessed in the comparative trial. Response rates were assessed based on World Health Organization (WHO) criteria, and in the comparative study, were submitted to an external review committee that was blinded to patient treatment. In the comparative study, 769 patients were randomized to receive AROMASIN (exemestane tablets) 25 mg once daily (N = 366) or megestrol acetate 40 mg four times daily (N = 403). Demographics and baseline characteristics are presented in Table 9.

Table 9. Demographics and Baseline Characteristics from the Comparative Study of Postmenopausal Women with Advanced Breast Cancer Whose Disease Had Progressed after Tamoxifen Therapy

Parameter AROMASIN
(N = 366)
Megestrol Acetate
(N = 403)
Median Age (range) 65 (35–89) 65 (30–91)
ECOG Performance Status    
  0 167 (46%) 187 (46%)
  1 162 (44%) 172 (43%)
  2 34 (9%) 42 (10%)
Receptor Status    
  ER and/or PgR + 246 (67%) 274 (68%)
  ER and PgR unknown 116 (32%) 128 (32%)
    Responders to prior tamoxifen 68 (19%) 85 (21%)
    NE for response to prior tamoxifen 46 (13%) 41 (10%)
Site of Metastasis    
  Visceral ± other sites 207 (57%) 239 (59%)
  Bone only 61 (17%) 73 (18%)
  Soft tissue only 54 (15%) 51 (13%)
  Bone & soft tissue 43 (12%) 38 (9%)
Measurable Disease 287 (78%) 314 (78%)
Prior Tamoxifen Therapy    
  Adjuvant or Neoadjuvant 145 (40%) 152 (38%)
  Advanced Disease, Outcome    
    CR, PR, or SD > 6 months 179 (49%) 210 (52%)
    SD < 6 months, PD or NE 42 (12%) 41 (10%)
Prior Chemotherapy    
  For advanced disease ± adjuvant 58 (16%) 67 (17%)
  Adjuvant only 104 (28%) 108 (27%)
  No chemotherapy 203 (56%) 226 (56%)

The efficacy results from the comparative study are shown in Table 10. The objective response rates observed in the two treatment arms showed that AROMASIN was not different from megestrol acetate. Response rates for AROMASIN from the two single-arm trials were 23.4% and 28.1%.

Table 10. Efficacy Results from the Comparative Study of Postmenopausal Women with Advanced Breast Cancer Whose Disease Had Progressed after Tamoxifen Therapy

Response Characteristics AROMASIN (N=366) Megestrol Acetate
(N=403)
Objective Response Rate = CR + PR (%) 15.0 12.4
  Difference in Response Rate (AR-MA) 2.6
  95% C.I. 7.5, -2.3
CR (%) 2.2 1.2
PR (%) 12.8 11.2
  SD ≥ 24 Weeks (%) 21.3 21.1
Median Duration of Response (weeks) 76.1 71.0
Median TTP (weeks) 20.3 16.6
    Hazard Ratio (AR-MA) 0.84
Abbreviations: CR = complete response, PR = partial response, SD = stable disease (no change), TTP = time to tumor progression, C.I. = confidence interval, MA = megestrol acetate, AR = AROMASIN

There were too few deaths occurring across treatment groups to draw conclusions on overall survival differences. The Kaplan-Meier curve for time to tumor progression in the comparative study is shown in Figure 2.

Figure 2. Time to Tumor Progression in the Comparative Study of Postmenopausal Women With Advanced Breast Cancer Whose Disease Had Progressed After Tamoxifen Therapy

Uses of Aromasin

Aromasin is a prescription medication used in women who are past menopause. It is used in:

Early breast cancer (cancer that has not spread outside the breast). It is for women who:

  • Have cancer that needs the female hormone estrogen to grow

  • Had surgery for breast cancer, and possibly other treatments for breast cancer including radiation or chemotherapy

  • Have taken tamoxifen for 2 to 3 years

  • Are switching to Aromasin to finish 5 years in a row of hormonal therapy

Advanced breast cancer (cancer that has spread), to treat cancer that came back after treatment with tamoxifen.

This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.

 

Aromasin Drug Class

Aromasin is part of the drug class:

  • Aromatase inhibitors

Aromasin Interactions

Tell your doctor about all the medicines you take. Include prescription and nonprescription medicines, herbal remedies, and vitamins. Aromasin and other medicines may affect how each other work.

Be sure to tell your doctor if you take:

  • Medicines with estrogen, such as Premarin, other hormone replacement therapy, or birth control pills or patches. Aromasin should not be taken with these medicines as they could affect how well Aromasin works.
  • Rifadin (rifampin)
  • Dilantin (phenytoin), Tegretol (carbamazepine), or Luminal (phenobarbital)
  • St. John's wort

Know what medicines you take. Keep a list of them with you. Show it to your doctor or pharmacist each time you get a new prescription.

 

Other Requirements

  • Keep Aromasin and all medicines out of the reach of children.
  • Store Aromasin at room temperature, 77°F (25°C), in its original container.

Pregnancy & Lactation

Pregnancy Category: X

Lactation: Excretion in milk unknown; because of potential for serious adverse reactions in breast-fed infants, advise women not to breastfeed during treatment and for 1 month after final dose

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

What is the most important information I should know about exemestane?

You should not use exemestane if you have not started menopause, or if you are pregnant or able to become pregnant.

Do not use exemestane if you are pregnant. It could harm the unborn baby.

What should I discuss with my healthcare provider before taking exemestane?

You should not use exemestane if you are allergic to it, or:

  • if you are pregnant or able to become pregnant; or

  • if you have not yet completed menopause, and are still having menstrual periods.

To make sure exemestane is safe for you, tell your doctor if you have:

  • liver disease; or

  • kidney disease.

Exemestane can decrease bone mineral density, which may increase your risk of developing osteoporosis. Talk to your doctor about your individual risk of bone loss.

Although it is not likely that a postmenopausal woman would be pregnant, exemestane can cause birth defects. Do not take this medicine if you are pregnant or may become pregnant. You may need to have a negative pregnancy test before starting this treatment.

If you are not past menopause, use effective birth control to prevent pregnancy while you are taking exemestane and for at least 1 month after your last dose. Tell your doctor right away if you become pregnant while taking exemestane.

It is not known whether exemestane passes into breast milk or if it could harm a nursing baby. You should not breast-feed while using this medicine.

Introduction

Antineoplastic agent; irreversible, selective steroidal aromatase inhibitor (type I), structurally related to the natural substrate androstenedione.1 2 3 4 5 6

Stability

Storage

Oral

Tablets

25°C (may be exposed to 15–30°C).1

Actions

  • Acts as a false substrate and is converted by aromatase to reactive alkylating intermediates that bind covalently to the substrate binding site of the enzyme; this irreversible binding to the active site of aromatase results in its inactivation (i.e., “suicide” inhibition).1 2 4 5 6

  • Selectively inhibits conversion of androgens to estrogens;1 2 4 5 6 resulting reduction in serum and tumor concentrations of estrogen inhibits tumor growth and delays disease progression.1 6

  • Selectively inhibits synthesis of estrogens; does not affect synthesis of adrenal corticosteroid, aldosterone, or thyroid hormone.1 2 3 6

  • Dose-dependent decrease in sex hormone binding globulin (SHBG) observed with dosages ≥ 2.5 mg daily.1 2

  • Slight, dose-independent increases in serum LH and FSH concentrations observed even at low dosages as result of negative feedback on the pituitary gland.1 2 3

  • At dosages ≤25 mg daily, no clinically important effect on circulating concentrations of androstenedione, dehydroepiandrostenedione sulfate, or 17-hydroxyprogesterone and only small decreases in circulating concentrations of testosterone observed.1 3

  • At dosages ≥200 mg daily, testosterone and androstenedione concentrations are increased.1 3 17-Hydroexemestane, a metabolite, exhibits substantial intrinsic androgenic activity, which may become clinically important at high (e.g., 200 mg daily) dosages.1 2 3

Commonly used brand name(s)

In the U.S.

  • Aromasin

Available Dosage Forms:

  • Tablet

Therapeutic Class: Antineoplastic Agent

Pharmacologic Class: Aromatase Inhibitor

What do I need to tell my doctor BEFORE I take Aromasin?

  • If you have an allergy to exemestane or any other part of Aromasin (exemestane).
  • If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.
  • If you have not been through menopause or you are still able to have a baby.
  • If you are taking estrogen products.
  • If you are breast-feeding. Do not breast-feed while you take this medicine or for 1 month after you stop Aromasin.

This is not a list of all drugs or health problems that interact with this medicine.

Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take Aromasin with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.

Aromasin Description

Aromasin® Tablets for oral administration contain 25 mg of exemestane, an irreversible, steroidal aromatase inactivator. Exemestane is chemically described as 6-methylenandrosta-1,4-diene-3,17-dione. Its molecular formula is C20H24O2 and its structural formula is as follows:

The active ingredient is a white to slightly yellow crystalline powder with a molecular weight of 296.41. Exemestane is freely soluble in N, N-dimethylformamide, soluble in methanol, and practically insoluble in water.

Each Aromasin Tablet contains the following inactive ingredients: mannitol, crospovidone, polysorbate 80, hypromellose, colloidal silicon dioxide, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, simethicone, polyethylene glycol 6000, sucrose, magnesium carbonate, titanium dioxide, methylparaben, and polyvinyl alcohol.

Clinical Studies

Adjuvant Treatment in Early Breast Cancer

The Intergroup Exemestane Study 031 (IES) was a randomized, double-blind, multicenter, multinational study comparing exemestane (25 mg/day) vs. tamoxifen (20 or 30 mg/day) in postmenopausal women with early breast cancer. Patients who remained disease-free after receiving adjuvant tamoxifen therapy for 2 to 3 years were randomized to receive an additional 3 or 2 years of Aromasin or tamoxifen to complete a total of 5 years of hormonal therapy.

The primary objective of the study was to determine whether, in terms of disease-free survival, it was more effective to switch to Aromasin rather than continuing tamoxifen therapy for the remainder of five years. Disease-free survival was defined as the time from randomization to time of local or distant recurrence of breast cancer, contralateral invasive breast cancer, or death from any cause.

The secondary objectives were to compare the two regimens in terms of overall survival and long-term tolerability. Time to contralateral invasive breast cancer and distant recurrence-free survival were also evaluated.

A total of 4724 patients in the intent-to-treat (ITT) analysis were randomized to Aromasin (exemestane tablets) 25 mg once daily (N = 2352) or to continue to receive tamoxifen once daily at the same dose received before randomization (N = 2372). Demographics and baseline tumor characteristics are presented in Table 5. Prior breast cancer therapy is summarized in Table 6.

Table 5. Demographic and Baseline Tumor Characteristics from the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)
Parameter Exemestane
(N = 2352)
Tamoxifen
(N = 2372)
* Results for receptor status include the results of the post-randomization testing of specimens from subjects for whom receptor status was unknown at randomization. † Only one subject in the exemestane group had unknown ER status and positive PgR status.
Age (years):
Median age (range) 63.0 (38.0 – 96.0) 63.0 (31.0 – 90.0)
Race, n (%):
Caucasian 2315 (98.4) 2333 (98.4)
Hispanic 13 (0.6) 13 (0.5)
Asian 10 (0.4) 9 (0.4)
Black 7 (0.3) 10 (0.4)
Other/not reported 7 (0.3) 7 (0.3)
Nodal status, n (%):
Negative 1217 (51.7) 1228 (51.8)
Positive 1051 (44.7) 1044 (44.0)
  1–3 Positive nodes 721 (30.7) 708 (29.8)
  4–9 Positive nodes 239 (10.2) 244 (10.3)
  >9 Positive nodes 88 (3.7) 86 (3.6)
  Not reported 3 (0.1) 6 (0.3)
Unknown or missing 84 (3.6) 100 (4.2)
Histologic type, n (%):
Infiltrating ductal 1777 (75.6) 1830 (77.2)
Infiltrating lobular 341 (14.5) 321 (13.5)
Other 231 (9.8) 213 (9.0)
Unknown or missing 3 (0.1) 8 (0.3)
Receptor status*, n (%):
ER and PgR Positive 1331 (56.6) 1319 (55.6)
ER Positive and PgR Negative/Unknown 677 (28.8) 692 (29.2)
ER Unknown and PgR Positive†/Unknown 288 (12.2) 291 (12.3)
ER Negative and PgR Positive 6 (0.3) 7 (0.3)
ER Negative and PgR Negative/Unknown (none positive) 48 (2.0) 58 (2.4)
Missing 2 (0.1) 5 (0.2)
Tumor Size, n (%):
≤ 0.5 cm 58 (2.5) 46 (1.9)
> 0.5 – 1.0 cm 315 (13.4) 302 (12.7)
> 1.0 – 2 cm 1031 (43.8) 1033 (43.5)
> 2.0 – 5.0 cm 833 (35.4) 883 (37.2)
> 5.0 cm 62 (2.6) 59 (2.5)
Not reported 53 (2.3) 49 (2.1)
Tumor Grade, n (%):
G1 397 (16.9) 393 (16.6)
G2 977 (41.5) 1007 (42.5)
G3 454 (19.3) 428 (18.0)
G4 23 (1.0) 19 (0.8)
Unknown/Not Assessed/Not reported 501 (21.3) 525 (22.1)
Table 6. Prior Breast Cancer Therapy of Patients in the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)
Parameter Exemestane
(N = 2352)
Tamoxifen
(N = 2372)
* The 30 mg dose was used only in Denmark, where this dose was the standard of care.
Type of surgery, n (%):
Mastectomy 1232 (52.4) 1242 (52.4)
Breast-conserving 1116 (47.4) 1123 (47.3)
Unknown or missing 4 (0.2) 7 (0.3)
Radiotherapy to the breast, n (%):
Yes 1524 (64.8) 1523 (64.2)
No 824 (35.5) 843 (35.5)
Not reported 4 (0.2) 6 (0.3)
Prior therapy, n (%):
Chemotherapy 774 (32.9) 769 (32.4)
Hormone replacement therapy 567 (24.1) 561 (23.7)
Bisphosphonates 43 (1.8) 34 (1.4)
Duration of tamoxifen therapy at randomization (months):
Median (range) 28.5 (15.8 – 52.2) 28.4 (15.6 – 63.0)
Tamoxifen dose, n (%):
20 mg 2270 (96.5) 2287 (96.4)
30 mg* 78 (3.3) 75 (3.2)
Not reported 4 (0.2) 10 (0.4)

After a median duration of therapy of 27 months and with a median follow-up of 34.5 months, 520 events were reported, 213 in the Aromasin group and 307 in the tamoxifen group (Table 7).

Table 7. Primary Endpoint Events (ITT Population)
Event First Events
N (%)
Exemestane
(N = 2352)
Tamoxifen
(N = 2372)
Loco-regional recurrence 34 (1.45) 45 (1.90)
Distant recurrence 126 (5.36) 183 (7.72)
Second primary – contralateral breast cancer 7 (0.30) 25 (1.05)
Death – breast cancer 1 (0.04) 6 (0.25)
Death – other reason 41 (1.74) 43 (1.81)
Death – missing/unknown 3 (0.13) 5 (0.21)
Ipsilateral breast cancer 1 (0.04) 0
Total number of events 213 (9.06) 307 (12.94)

Disease-free survival in the intent-to-treat population was statistically significantly improved [Hazard Ratio (HR) = 0.69, 95% CI: 0.58, 0.82, P = 0.00003, Table 8, Figure 1] in the Aromasin arm compared to the tamoxifen arm. In the hormone receptor-positive subpopulation representing about 85% of the trial patients, disease-free survival was also statistically significantly improved (HR = 0.65, 95% CI: 0.53, 0.79, P = 0.00001) in the Aromasin arm compared to the tamoxifen arm. Consistent results were observed in the subgroups of patients with node negative or positive disease, and patients who had or had not received prior chemotherapy.

An overall survival update at 119 months median follow-up showed no significant difference between the two groups, with 467 deaths (19.9%) occurring in the Aromasin group and 510 deaths (21.5%) in the tamoxifen group.

Table 8. Efficacy Results from the IES Study in Postmenopausal Women with Early Breast Cancer
ITT Population Hazard Ratio
(95% CI)
p-value
(log-rank test)
* Not adjusted for multiple testing.
Disease-free survival 0.69 (0.58–0.82) 0.00003
Time to contralateral breast cancer 0.32 (0.15–0.72) 0.00340
Distant recurrence-free survival 0.74 (0.62–0.90) 0.00207
Overall survival 0.86 (0.67–1.10) 0.22962
ER and/or PgR positive
Disease-free survival 0.65 (0.53–0.79) 0.00001
Time to contralateral breast cancer 0.22 (0.08–0.57) 0.00069
Distant recurrence-free survival 0.73 (0.59–0.90) 0.00367
Overall survival 0.91 (0.81–1.04) 0.16*
Figure 1. Disease-Free Survival in the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)

Treatment of Advanced Breast Cancer

Exemestane 25 mg administered once daily was evaluated in a randomized double-blind, multicenter, multinational comparative study and in two multicenter single-arm studies of postmenopausal women with advanced breast cancer who had disease progression after treatment with tamoxifen for metastatic disease or as adjuvant therapy. Some patients also have received prior cytotoxic therapy, either as adjuvant treatment or for metastatic disease.

The primary purpose of the three studies was evaluation of objective response rate (complete response [CR] and partial response [PR]). Time to tumor progression and overall survival were also assessed in the comparative trial. Response rates were assessed based on World Health Organization (WHO) criteria, and in the comparative study, were submitted to an external review committee that was blinded to patient treatment. In the comparative study, 769 patients were randomized to receive Aromasin (exemestane tablets) 25 mg once daily (N = 366) or megestrol acetate 40 mg four times daily (N = 403). Demographics and baseline characteristics are presented in Table 9.

Table 9. Demographics and Baseline Characteristics from the Comparative Study of Postmenopausal Women with Advanced Breast Cancer Whose Disease Had Progressed after Tamoxifen Therapy
Parameter Aromasin
(N = 366)
Megestrol Acetate
(N = 403)
Median Age (range) 65 (35–89) 65 (30–91)
ECOG Performance Status
  0 167 (46%) 187 (46%)
  1 162 (44%) 172 (43%)
  2 34 (9%) 42 (10%)
Receptor Status
  ER and/or PgR + 246 (67%) 274 (68%)
  ER and PgR unknown 116 (32%) 128 (32%)
    Responders to prior tamoxifen 68 (19%) 85 (21%)
    NE for response to prior tamoxifen 46 (13%) 41 (10%)
Site of Metastasis
  Visceral ± other sites 207 (57%) 239 (59%)
  Bone only 61 (17%) 73 (18%)
  Soft tissue only 54 (15%) 51 (13%)
  Bone & soft tissue 43 (12%) 38 (9%)
Measurable Disease 287 (78%) 314 (78%)
Prior Tamoxifen Therapy
  Adjuvant or Neoadjuvant 145 (40%) 152 (38%)
  Advanced Disease, Outcome
    CR, PR, or SD ≥ 6 months 179 (49%) 210 (52%)
    SD < 6 months, PD or NE 42 (12%) 41 (10%)
Prior Chemotherapy
  For advanced disease ± adjuvant 58 (16%) 67 (17%)
  Adjuvant only 104 (28%) 108 (27%)
  No chemotherapy 203 (56%) 226 (56%)

The efficacy results from the comparative study are shown in Table 10. The objective response rates observed in the two treatment arms showed that Aromasin was not different from megestrol acetate. Response rates for Aromasin from the two single-arm trials were 23.4% and 28.1%.

Table 10. Efficacy Results from the Comparative Study of Postmenopausal Women with Advanced Breast Cancer Whose Disease Had Progressed after Tamoxifen Therapy
Response Characteristics Aromasin
(N=366)
Megestrol Acetate
(N=403)
Abbreviations: CR = complete response, PR = partial response, SD = stable disease (no change), TTP = time to tumor progression, C.I. = confidence interval, MA = megestrol acetate, AR = Aromasin
Objective Response Rate = CR + PR (%) 15.0 12.4
    Difference in Response Rate (AR-MA)
2.6
    95% C.I. 7.5, -2.3
CR (%) 2.2 1.2
PR (%) 12.8 11.2
  SD ≥ 24 Weeks (%) 21.3 21.1
Median Duration of Response (weeks) 76.1 71.0
Median TTP (weeks) 20.3 16.6
    Hazard Ratio (AR-MA) 0.84

There were too few deaths occurring across treatment groups to draw conclusions on overall survival differences. The Kaplan-Meier curve for time to tumor progression in the comparative study is shown in Figure 2.

Figure 2. Time to Tumor Progression in the Comparative Study of Postmenopausal Women With Advanced Breast Cancer Whose Disease Had Progressed After Tamoxifen Therapy

Important information

You should not use Aromasin if you are allergic to exemestane, if you have not started menopause, or if you are pregnant or able to become pregnant.

Do not use Aromasin if you are pregnant. It could harm the unborn baby.

Before using this medicine, tell your doctor if you have liver or kidney disease, or if you have not yet completed menopause and are still having menstrual periods.

Use Aromasin regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely. You may need to keep taking take this medicine for up to 5 years. Follow your doctor's instructions. Aromasin may not work as well if you take it together with hormone replacement medication, or while using birth control pills or patches.

What happens if I miss a dose?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

(web3)